Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ADC Therapeutics (ADCT) Income towards Parent Company (2019 - 2026)

ADC Therapeutics has reported Income towards Parent Company over the past 8 years, most recently at -$33.0 million for Q1 2026.

  • Quarterly results put Income towards Parent Company at -$33.0 million for Q1 2026, up 14.6% from a year ago — trailing twelve months through Mar 2026 was -$130.6 million (down 10.42% YoY), and the annual figure for FY2022 was -$155800.0, up 32.27%.
  • Income towards Parent Company reached -$33.0 million in Q1 2026 per ADCT's latest filing, up from -$41.0 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $64.4 million in Q2 2022 and bottomed at -$56.6 million in Q2 2025.
  • Median Income towards Parent Company over the past 5 years was -$16.5 million (2023), compared with a mean of -$11.7 million.
  • The largest annual shift saw Income towards Parent Company rose 29.74% in 2022 before it plummeted 91328.03% in 2024.
  • Over 5 years, Income towards Parent Company stood at -$24157.0 in 2022, then tumbled by 97.9% to -$47807.0 in 2023, then tumbled by 91328.03% to -$43.7 million in 2024, then rose by 6.28% to -$41.0 million in 2025, then grew by 19.52% to -$33.0 million in 2026.
  • Business Quant data shows Income towards Parent Company for ADCT at -$33.0 million in Q1 2026, -$41.0 million in Q3 2025, and -$56.6 million in Q2 2025.